Full Text View
Tabular View
No Study Results Posted
Related Studies
A Comparison of Two Total Hip Replacements: Hip Resurfacing System Versus Mallory-Head/Exeter
This study is ongoing, but not recruiting participants.
First Received: June 30, 2005   Last Updated: December 3, 2008   History of Changes
Sponsors and Collaborators: University of Aarhus
Biomet Merck Aps,Horsens, Denmark
Gigtforeningen,Gentoftegade 118, Gentofte, Denmark
Sahva A/S, Borgervænget 5-7, København Ø, Denmark
Danske Fysioterapeuter,Nørre Voldgade 90, København, Denmark
Silkeborg Hospital, Denmark
The Finnish Institute of Occ. Health Biomonitoring Lab., Helsinki, Finland
Hammel Neurocenter, Hammel, Denmark
Information provided by: University of Aarhus
ClinicalTrials.gov Identifier: NCT00116948
  Purpose

The purpose of this study is to compare two total hip replacement systems: Hip Resurfacing System (ReCap) versus Mallory-Head/Exeter.


Condition Intervention Phase
Osteoarthrosis
Device: ReCap, Hip resurfacing system, Biomet
Phase IV

MedlinePlus related topics: Osteoarthritis
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind (Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Comparison of Two Total Hip Replacements: Hip Resurfacing System Versus Mallory-Head/Exeter

Further study details as provided by University of Aarhus:

Primary Outcome Measures:
  • Metal ion release evaluated in urine [ Time Frame: three years ] [ Designated as safety issue: No ]
  • Gait pattern evaluated with 3D gait analysis, Vicon Polygon [ Time Frame: two years ] [ Designated as safety issue: No ]
  • Bone mineral density (BMD) in surrounding bone of the prosthesis [ Time Frame: three years ] [ Designated as safety issue: No ]
  • Prostheses migration evaluated by radiostereometric analysis (RSA) [ Time Frame: three years ] [ Designated as safety issue: No ]
  • Proinflammatory- and bone degradation measures in blood samples [ Time Frame: three years ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: January 2005
Estimated Study Completion Date: January 2010
Estimated Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: ReCap, Hip resurfacing system, Biomet
    ReCap total hip arthroplasty inserted according to manufactures manual.
Detailed Description:

In Denmark approximately 7000 primary hip replacements are implanted yearly, and the incidence is rising with the increasingly aging population. For older patients, the incidence of later revisions of hip implantation is low. Unfortunately, this is not true for younger patients. Approximately 20% of patients under 55 years of age at the time of surgery must have the hip implant renewed within 10 years.

This is primarily because of the wear generated by polyethylene debris. The polyethylene is associated with osteolysis in the proximity of the prosthesis leading to failure of the prosthesis. This unsatisfactory result has led to the development of an alternative hip prosthesis especially to benefit younger and physically active people. The new prosthesis should produce less inflammatory debris and less osteolysis induced failure.

To avoid the polyethylene particles, a new type of prosthesis has been made articulating metal on metal. The Hip Resurfacing System consists of an alloy of chrome - cobalt - molybdenum. Another point of interest for this prosthesis is also the size of the articulating surfaces which are bigger than usual.

This will theoretically participate in the generation of metal ions.

Study objectives:

  • This randomised prospective study will investigate the emission of Co-, Cr- and Mb-ions from Hip Resurfacing System and Mallory-Head/Exeter implants, respectively. The emission is measured as the ion concentration in the urine and is correlated to the inflammatory response in fasting plasma before and after the operation.
  • To assess the walking pattern postoperatively using a 3D gait analysis, Vicon Polygon.
  • To assess the postoperative recovery using the Harris hip score and visual analogue scale.
  • The migration of acetabular components will be evaluated by RSA, performing radiostereometric analyses at the Orthopaedic Center, Aarhus University Hospital. The follow-up RSA will be scheduled for week 1, as well as 3 months, 12 months, 24 months, and 5 years after surgery. Bone mineral density around the implanted femoral component will be examined by DEXA scan at week 1, as well as 1 year and 2 years after surgery.
  Eligibility

Ages Eligible for Study:   50 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient with primary hip osteoarthrosis (OA).
  • Informed patient consent in writing.
  • Sufficient bone density to allow uncemented implantation of an acetabular component.

Exclusion Criteria:

  • Presence of other metal implants.
  • Working exposure of chrome, cobalt or molybdenum.
  • Ingestion of multivitamin or medication containing chrome, cobalt or molybdenum.
  • Kidney disease
  • Hip joint dysplasia
  • Patients with neuromuscular or vascular disease in the affected leg.
  • Patients who regularly take non-steroid anti-inflammatory drugs (NSAID) and cannot interrupt intake for the postoperative phase of the study.
  • Patients with fracture sequelae.
  • Female patients of childbearing capacity.
  • Sequelae to previous hip joint disorder in childhood
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00116948

Locations
Denmark, Jylland
Orthopaedic Center, Aarhus University Hospital
Aarhus, Jylland, Denmark, 8000
Sponsors and Collaborators
University of Aarhus
Biomet Merck Aps,Horsens, Denmark
Gigtforeningen,Gentoftegade 118, Gentofte, Denmark
Sahva A/S, Borgervænget 5-7, København Ø, Denmark
Danske Fysioterapeuter,Nørre Voldgade 90, København, Denmark
Silkeborg Hospital, Denmark
The Finnish Institute of Occ. Health Biomonitoring Lab., Helsinki, Finland
Hammel Neurocenter, Hammel, Denmark
Investigators
Principal Investigator: Kjeld Søballe, MD., Prof. Orthopaedic Center, Aarhus University Hospital, Aarhus, Denmark
  More Information

No publications provided

Responsible Party: Aarhus University Hospital ( Professor Kjeld Søballe )
Study ID Numbers: 20030289
Study First Received: June 30, 2005
Last Updated: December 3, 2008
ClinicalTrials.gov Identifier: NCT00116948     History of Changes
Health Authority: Denmark: The Regional Committee on Biomedical Research Ethics

Keywords provided by University of Aarhus:
Osteoarthrosis
RSA
DEXA
Hip arthroplasty
Metal ion
Inflammatory response
Gait analysis

Study placed in the following topic categories:
Musculoskeletal Diseases
Osteoarthritis
Arthritis
Joint Diseases
Rheumatic Diseases
Cimetidine

Additional relevant MeSH terms:
Musculoskeletal Diseases
Osteoarthritis
Arthritis
Joint Diseases
Rheumatic Diseases

ClinicalTrials.gov processed this record on May 07, 2009